Pimavanserin for the treatment of schizophrenia & Alzheimer's Disease Psychosis Next. LINK
2 Biopharma Stocks Rallying On Fresh Clinical Trial Data
March 21 2013,
Ultimately I think that Acadia could see a lot more interest in the next few trading sessions as investors think about the huge prospects that this drug could have in an untreatable neurodegenerative disease, and while we move closer to a potential NDA submission. These results also bode well for Pimavanserin's other development programs, which include Pimavanserin for the treatment of schizophrenia and Alzheimer's Disease Psychosis (ADP).